Collaboration brings together Schrödinger’s in silico discovery capabilities with SPARC’s novel insights into CNS pathways to speed drug development
MUMBAI and NEW YORK – December 03, 2018 – Schrödinger and Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) today announced a research collaboration to accelerate the discovery of novel CNS therapeutics by leveraging
Schrödinger’s advanced computational platform and SPARC’s extensive drug development expertise and insights in neurodegeneration. Schrödinger, a privately held company committed to revolutionizing drug discovery through advanced
molecular simulation, will focus on lead discovery and optimization. SPARC, a clinical-stage company focused on improving patient care through innovation, will be responsible for compound synthesis and assays.
“This research collaboration is particularly exciting because neurodegeneration is an area where we urgently need more options for patients through novel approaches to drug discovery and development,” said Ramy Farid, Ph.D., president and CEO of Schrödinger. “SPARC has been working with leading academic researchers to explore pathways relevant to disorders of the central nervous system, and their insights are quite compelling. Teaming up will allow us to rapidly interrogate therapeutic compounds that target these pathways.”
“We have used Schrödinger’s software for years and have experienced directly the power of their physics-based approaches to computational modeling, so we’re delighted to form a collaboration that lets us tap into the expertise of their drug discovery team as well,” said Anil Raghavan, CEO of SPARC. “At
SPARC, we’re committed to fueling innovation through both internal R&D and strategic partnerships with industry leaders, and this collaboration is a strong step in that direction. By working together, we can greatly accelerate the pace of innovation.”